Heart Test Laboratories, Inc. (HSCS) Short-Term Debt to Capital

Heart Test Laboratories is actively integrating neural networks into ECGs for precise cardiac screening by 2026, leveraging cardiologists' trust in its early pathology detection methods. The market price on GURU.Markets, as confirmed by this chart, recorded a value of 0.00. High business scalability is driven by MyoVista cloud data analysis, transforming diagnostic tests into a high-margin SaaS model with minimal costs.

FDA certification delays for the AI platform and liquidity shortages during preparations for the commercial launch of Heart Test Laboratories make the short interest to equity chart a critical indicator, measuring the business's reliance on urgent liabilities relative to its net assets, where rising peaks signal financial instability risks and a decline in the asset's investment reliability.